Yes. Aqueduct Technologies has a dedicated software and renewals practice that helps organizations identify savings in their existing license and subscription portfolios. In one engagement with a large publicly traded biopharma company, Aqueduct completed a full review of current assets, upcoming renewals, and usage levels in one week — identifying opportunities to consolidate subscriptions into lower-cost enterprise agreements and securing extended payment terms of 60 to 180 days. The result was a 33% reduction in total cost of ownership and the ability to defer 90% of cash outlay by six months or more.
